# SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

> **NCT03126461** · PHASE2 · WITHDRAWN · sponsor: **University of Texas Southwestern Medical Center**

## Conditions studied

- Melanoma
- Metastatic Melanoma

## Interventions

- **RADIATION:** SAbR
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03126461
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** the project was never initiated and no participants were enrolled, it was closed permanently
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126461, "SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03126461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*